# INTELLIA THERAPEUTICS, INC. (NTLA) · Edgar & Edgarette company card

> Intellia Therapeutics (NTLA) grew revenue 16.9% in FY2025 to $68 million, operating margin -652% against a -4.3% median for in vitro & in vivo diagnostic substances, equity 79.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1652130 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/NTLA) · [JSON](https://www.pops4.com/boards/company/NTLA.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $68M |
| Revenue growth, 1 year | 16.9% |
| Revenue growth per year | 19.6% |
| Operating margin | -651.7% (prior year -923.1%) |
| Net margin | -609.9% |
| Operating cash flow | −$395M |
| Capital spending | $1M |
| Free cash flow | −$396M |
| Cash | $155M |
| Long-term debt | — |
| Total assets | $842M |
| Total equity | $671M |
| Equity ÷ assets | 79.7% |
| Return on equity | -61.5% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -6.12 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -651.7% in FY2025; revenue is hard to predict: its 80% range is ±64%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $67.7M (FY2025). Experience: revenue up 16.9% on the year, up 19.6% a year over 4 years; operating margin -651.7%, up from -923.1%. Soundness: equity 79.7% of assets, return on equity -61.5%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $33.9M and $157.0M next year (method v4.1: its own 6-year record of growth weighed at 63% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $35.9M to $148.8M. A statistical range, not company guidance. Against peers (161 filers, $50M+ revenue, its industry group): operating margin -651.7% against a -4.3% median; growth 16.9% against 12.6%.

Range logged 2026-09-25, receipt 80173d7104787b66, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 8-K · filed 2026-09-08 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1652130/000119312526385194/0001193125-26-385194-index.htm)
- 8-K · filed 2026-09-04 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1652130/000119312526383645/0001193125-26-383645-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/0001193125-26-337952-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1652130/000119312526336772/0001193125-26-336772-index.htm)
- 8-K · filed 2026-06-15 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1652130/000119312526270358/0001193125-26-270358-index.htm)
- 8-K · filed 2026-06-10 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1652130/000119312526265934/0001193125-26-265934-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001652130.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1652130

## Cite

POPS4, Edgar & Edgarette: INTELLIA THERAPEUTICS, INC. (NTLA) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/NTLA. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.